eISSN: 1897-4295
ISSN: 1734-9338
Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
vol. 14
Original paper

Clinical factors predicting blood pressure reduction after catheter-based renal denervation

Krzysztof Bartus, Radosław Litwinowicz, Jerzy Sadowski, Wojciech Zajdel, Maciej Brzeziński, Magdalena Bartus, Paweł Kleczyński, Stanislaw Bartus, Dhanunjaya Lakkireddy, Bogusław Kapelak

Adv Interv Cardiol 2018; 14, 3 (53): 270–275
Online publish date: 2018/09/21
Article file
- clinical factors.pdf  [0.15 MB]
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero


Catheter-based renal nerve ablation with radiofrequency energy via the renal artery can lead to a significant and sustained decrease in mean values of arterial systolic and diastolic blood pressure (BP) in patients with resistant hypertension (systolic BP < 160 mm Hg). The first procedure of renal denervation (RD) was performed by Krum et al. in 2009 [1]. The clinical trials Symplicity I and Symplicity II have shown that 84% of patients after RD had a significant decrease of BP, reaching mean systolic and diastolic depression by 30 and 14 mm Hg [1, 2].
Effective BP lowering therapy can lead to several subsequent benefits including reduction of cardiovascular mortality and morbidity [1–4] but also improvement of quality of life [5]. However, there is still a large group of non-responding patients, without significant blood pressure changes after RD. The first short-term results showed that 84% of the patients had BP ≥ 10 mm Hg and 39% had desirable BP (≤ 140 mm Hg) [1]. The reason for non-responsiveness to RD still remains to be clarified.


The aim of the study was to retrospectively compare RD responder patients to RD non-responders and find predictors of non-responsiveness for RD as well as clinical factors that might have a direct impact on the blood pressure reduction to increase the chances of procedural success.

Material and methods

Patients and procedure

All patients enrolled in the study were part of the HTN-1 and HTN-2 trials population. Adult patients with resistant arterial hypertension with systolic blood pressure over 160 mm Hg, receiving full doses of three antihypertensive drugs (including a diuretic) for at least 2 weeks before enrollment and with an estimated glomerular filtration rate over 45 ml/min who met all inclusion/exclusion criteria were eligible for this study. The presence of resistant arterial hypertension was defined as mean brachial artery seated systolic pressure above 160 mm Hg during out-patient department visits, despite historical compliance with at least three anti­hypertensive drugs (including a diuretic) in optimal doses. Blood pressure measurement was performed in accordance with Joint National Committee VII guidelines [6]. Measurements were performed each time by the same person, sitting, in triplicate and then averaged. The technique of renal denervation has recently been described [7–10]. After standard femoral vascular access, the SIMPLICITY catheter (Ardian Inc. USA Company, currently Medtronic Inc., USA) was introduced into each renal artery. During the procedure, a standard dose of unfractionated heparin was used. Six radiofrequency ablations at 8 W lasting up to 120 s each were performed in both renal arteries. Supplied energy, tip temperature and impedance were monitored by the catheter system in response to a predetermined algorithm during the procedure. Follow-up visits were performed at 1, 3, 6, 9, 12, 18, 24 and 36 months after the index procedure. Blood pressure (systolic, diastolic, pulse pressure) measurements were performed according to the methodology described earlier. Blood count, electro­lytes, urea, creatinine, urine and physical examinations including orthostatic BP measurements were performed. During the entire study major adverse events (death, stroke, myocardial infarction) or other outcomes associated with the procedure were monitored. Three years after the procedure we assessed the percentage reduction of the mean baseline blood pressure value. Patients were assigned to the “non-responders” group if the percentage reduction of systolic blood pressure was ≤ 10% than the baseline. Patients were assigned to the “responders” group if the percentage reduction of systolic blood pressure was at least 10% of mean systolic BP. Written informed consent was obtained from all patients. The study was approved by the institutional ethical board (two separate ethics committee approvals since the patients attended the SYMPLICITY HTN-1 and SYMPLICITY HTN-2 studies).


1. Multiple regression analysis of all factors was performed to find any determinants of BP reduction.
2. The group of patients with BP reduction after RD (responders) was compared to the group of patients without BP reduction after RD (non-responders).

Statistical analysis

Continuous variables were checked for normal distribution with the Shapiro-Wilk test. Data are expressed as mean  standard deviation or median (interquartile range) unless otherwise stated. To assess the differences between two continuous variables, Student’s t-test (for normally distributed values), or the Mann-Whitney U-test (for non-normally distributed values) was applied. To assess the differences between three continuous variables, the ANOVA test (for normally distributed values) or the Kruskal-Wallis-test (for non-normally distributed values) was applied. Categorical variables were compared by the 2 test or Fisher’s exact test, as appropriate. Multiple regression was calculated to assess the relationship between one dependent variable and one or more independent variables. Statistical analysis was performed with Statistica 10.0 (StatSoft, Tulsa, OK, USA). A two-sided p-value < 0.05 was considered statistically significant.


Before the procedure systolic BP from 160 to 170 mm Hg was present in 35.5% of patients; systolic BP above 170 to 180 mm Hg was present in 48.4% of patients; systolic BP above 180 mm Hg was present in 16.1% of patients. Patients’ characteristic are presented in Table I. After 3 years of follow-up a 10% or more reduction of systolic baseline BP was observed in 74% of patients. A 10% or more reduction of diastolic baseline BP was observed in 71% of patients. The mean value of systolic BP ranged from 110 to 211 mm Hg (mean value: 149.69 mm Hg) and it was 25.23 mm Hg lower than baseline BP. The mean percentage reduction was 14% in all patients. The mean value of diastolic BP ranged from 64 to 119 mm Hg (mean value: 85.17 mm Hg) and it was 14.65 mm Hg lower than baseline BP. The percentage reduction was 14%. Before ablation the mean systolic BP value of three measurements ranged from 162 to 212 mm Hg (mean value: 174.91 mm Hg). Target systolic BP ≤ 140 mm Hg was achieved in 35% and target diastolic BP ≤ 90 mm Hg was achieved in 71% of patients. Target systolic and diastolic ≤ 140/90 mm Hg was achieved in 35% of patients (Figure 1). Relationships between percentage reduction of baseline systolic BP and risk factors are present in Table II. A 20% reduction of baseline systolic blood pressure was observed in 35% of patients (high response patients). A reduction from 10% to 20% of baseline systolic blood pressure was observed in 39% of patients (normal response patients). Twenty-six percent of patients had no response for renal denervation.

Response patients – > 10% baseline systolic BP reduction

Twenty-two (71%) patients had > 10% reduction of mean baseline systolic BP. There were 10 females and 12 males (45% female and 55% male) in the response group. Patients’ age ranged from 43 to 76 (mean value: 57.04), weight ranged from 74 to 122 kg (mean value: 94.7 kg), height ranged from 159 to 184 cm (mean value: 169.3 cm) and body mass index (BMI) ranged from 23.36 to 39.41 kg/m2 (33.02 kg/m2).
Observed risk factors in this group were: hypercholesterolemia in 70%, BMI >30 kg/m2 in 55%, diabetes mellitus in 35%, current smoking in 5%. Comorbidity included coronary artery disease (CAD) in 30%, cardiomyopathy in 10%, chronic obstructive pulmonary disease (COPD) in 10%, renal insufficiency in 10%, and ventricular arrhythmia in 5%. Multivariate logistic regression analysis of risk factors in response patients is presented in Table II.

Non-response patients

Eight (26%) patients did not respond to renal denervation. This group consisted of 2 females and 6 males (25% female and 75% male). Patients’ age ranged from 31 to 72 (mean value: 56.1), weight ranged from 83 to 145 kg (mean value: 99.14 kg), height ranged from 160 to 176 cm (mean value: 168.86 cm) and BMI ranged from 29.39 to 46.81 kg/m2 (34.56 kg/m2). Observed risk factors in this group were: hypercholesterolemia in 38%, diabetes mellitus type 2 in 38% and BMI > 30 kg/m2 in 86%. Comorbidity included CAD in 50% and cardiomyopathy in 13% of patients.
Differences between clinical factors in regard to responders and non-responders are presented in Table III.


Radiofrequency renal nerve ablation is effective treatment in patients with resistant hypertension by reducing the level of blood pressure [1, 2, 8, 10]. Patients with resistant hypertension are at a higher risk of cardiovascular events and end-organ damage as compared to patients with adequately controlled hypertension [11]. The efficacy of the RD procedure has been assessed in several large studies. The Symplicity HTN-1 and randomized Symplicity HTN-2 trial demonstrated that RD is feasible, effective and safe in the treatment of resistant hypertension. In both studies, no adverse effects of RD on renal function were observed [1, 2]. However, the Symplicity HTN-1 and HTN-2 trials did not include only patients with bilateral single arteries. Further research showed that BP reduction can also be achieved in patients with accessory renal arteries [12]. The Symplicity HTN-3 trial suggested that 6 months after RD there were no significant differences in reduction of systolic BP in office or 24-hour ambulatory measurements as compared with a sham control [13]. The results of the Symplicity HTN-3 trial did not confirm the results of previous registries and trials with a potentially overestimated treatment effect; however, several limitations of the study design might have influenced the clinical outcomes [14, 15]. On the other hand, Symplicity HTN-3 confirmed the safety of the RD procedure. Based on the results of individual analyses, we can conclude that the final effect of RD will depend on many factors and this procedure may not be suitable for all patients. Identifying predictors which make RD effective is important to select patients who will respond adequately to treatment. Due to important uncertainties about RD, more research is required to provide conclusive evidence for antihypertensive long-term effects, safety, clinical outcomes and quality of life (QoL) improvement after RD. The additional benefits of RD observed in other studies were reduction of left ventricle mass and improvement of diastolic function. These might have important prognostic implications for patients with resistant hypertension at high cardiovascular risk [16]. Other studies have suggested a reduction in heart rate over 6 months [1, 17], as well as a positive effect on renal function [18], glucose metabolism and insulin sensitivity after RD [19]. In the present study, 3 years after the procedure, the mean BP value remained successfully reduced (> 10% reduction of baseline BP) in 74% of cases for systolic BP (response patients) and in 71% of cases for diastolic BP. Thirty-four percent of patients had > 20% reduction of baseline systolic BP, 39% had a 10% to 20% reduction of baseline systolic BP and 26% had less than a 10% reduction or the mean systolic BP was higher than the baseline BP (non-response patients). After renal denervation the systolic BP reduction was highest in the female group compared to the male group. Women were more frequently in the group of response patients (49% women vs. 51% men) whereas men were more frequently in the group of non-response patients (25% women vs. 75% men). It should be noted that female sex is associated with the highest risk of resistant hypertension [19]. In our study, renal denervation in women led to a 16% reduction (28.25 mm Hg) and in men to a 13% reduction (23.28 mm Hg) of baseline systolic BP. There was a trend towards better responsiveness for RD in older and taller patients and non-responsiveness in obese patients. However, there was not significant in the formal statistical sense (p < 0.05). The prevalence of hypercholesterolemia was higher in response patients (64%) compared to non-response patients (38%). Hypercholesterolemia is not a risk factor for resistant hypertension, but it may lead to vascular disease such as atherosclerosis or renal artery stenosis which can cause resistant hypertension [20]. Moreover, systolic BP reduction is more difficult to achieve in older patients [20]. In our study, renal denervation in all hypercholesterolemia patients led to a 16% reduction (28.28 mm Hg) of baseline systolic BP. Prevalence of diabetes type II, commonly associated with hypertension, was higher in response patients (present in 55.5%) compared to non-response patients (37.5%). Increased levels of insulin resistance cause a proportional increase in severity of hypertension. Patients with increased sympathetic nervous activity and vascular smooth muscle cell proliferation present increased sodium retention [21].
Therefore, in diabetes patients, denervation of sympathetic nerves decreases the level of sodium retention. Also diabetic patients need more antihypertensive medications (range: 2.8–4.2) to achieve target BP compared to non-diabetic patients [22]. Preliminary studies have shown that renal denervation is associated with a reduction in fasting glucose and insulin levels [23]. In our study, renal denervation in all diabetes mellitus type 2 patients led to a 17% reduction (29.41 mm Hg) of baseline systolic BP. Obesity was more frequent in the non-response group (present in 87.5%) compared to response patients (63.6%). Also, higher BMI values were present in non-response patients (34.56 kg/m2) compared to response patients (33 kg/m2). There were no significant differences between groups. Obesity is the main lifestyle risk factor for resistant hypertension [24] and with high BMI is associated with more severe hypertension and increased likelihood of never achieving optimal blood pressure [25]. It is assumed that pathophysiological increased activation of the sympathetic nervous system caused by obesity is one of the main reasons for resistant hypertension [26]. A recent study showed that renal denervation led to suppression of renal sympathetic nerve activity and reduction of total body noradrenaline [1, 26]. In our study, renal denervation in all obese patients led to a 13% reduction (22.15 mm Hg) of baseline systolic BP. Coronary artery disease was more frequent in non-response patients (50%) compared to response patients (27%). A recent study suggested that renal denervation, despite BP reduction, also has beneficial effects on heart disease. Improvements in symptoms and exercise capacity in patients with chronic systolic heart failure were confirmed by Davies et al. [27]. Other benefits for the cardiovascular system after renal denervation are: improvement of cardiac diastolic function, reduction of left ventricular mass and reduction of the augmentation index [28, 29]. The theoretical potential of renal denervation in cardiac arrhythmia is currently being investigated [30].
A recent study suggested that renal denervation, despite BP reduction, also has beneficial effects on heart disease like the improvement of cardiac diastolic function, reduction of left ventricular mass, reduction of the augmentation index and exercise capacity [21, 29, 30]. The theoretically potential of renal denervation on cardiac arrhythmia is currently investigated [30].
Renal insufficiency was observed only in high response patients (18%). Renal diseases are a common cause of resistant hypertension [26]. Renal denervation is a potential therapeutic option for hemodialysis patients with resistant or difficult to control hypertension. In our study, renal denervation in renal insufficiency patients led to a 22% reduction (22.93 mm Hg) of baseline systolic BP.
Resistant hypertension is a specific disease with complex etiology often comorbid with other diseases that require multidisciplinary treatment. Denervation (ablation) of sympathetic fibers in renal arteries is an effective and safe treatment in resistant hypertensive patients, as has been proven by numerous clinical studies. However, there is a group of patients who do not respond to treatment. Nevertheless, there are numerous groups of patients with comorbid disease in whom renal denervation brings a number of additional therapeutic and clinical benefits. In our opinion, thoughtful selection of patients’ enrollment in the ablation procedure will further enhance the benefits of the procedure and extend the range of indications for renal denervation. Due to the small number of patients in our analysis, a multicenter study should be performed for more detailed characteristics of patients who underwent renal denervation.


A 10% reduction of systolic baseline BP was observed in 74% of patients three years after renal denervation.
Clinical factors like COPD, chronic kidney disease 3a, female sex and hypercholesterolemia increase the chances of effective reduction of BP. However, due to the small number of patients, there was no statistically significant difference between these factors.

Conflict of interest

The authors declare no conflict of interest. References 1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-81.
2. Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-9.
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38.
4. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003; 362: 1527-35.
5. Krawczyk-Ozog A, Tokarek T, Moczala K, et al. Long-term quality of life and clinical outcomes in patients with resistant hypertension treated with renal denervation. Adv Interv Cardiol 2016; 12: 329-33.
6. Muntner P, Krousel-Wood M, Hyre AD, et al. Antihypertensive prescriptions for newly treated patients before and after the main antihypertensive and lipid-lowering treatment to prevent heart attack trial results and seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure guidelines. Hypertension 2009; 53: 617-23.
7. Bartus K, Sadowski J, Kapelak B, et al. Denervation of nerve terminals in renal arteries: one-year follow-up of interventional treatment of arterial hypertension. Kardiol Pol 2014; 72: 425-31.
8. Bartus K, Sadowski J, Kapelak B, et al. Denervation (ablation) of nerve terminalis in renal arteries: early results of interventional treatment of arterial hypertension in Poland. Kardiol Pol 2013; 71: 152-8.
9. Esler MD, Bohm M, Sievert H, et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. Eur Heart J 2014; 35: 1752-9.
10. Bartus K, Sadowski J, Kapelak B, et al. Renal denervation – interventional radiofrequency treatment of arterial hypertension. Two years follow-up. Kardiol Pol 2017.
11. Januszewicz A, Witkowski A. Renal denervation – where do we stand in 2014? Postep Kardiol Interw 2014; 10: 1.
12. Bartus K, Podolec J, Sadowski J, et al. Blood pressure reduction in patients with accessory renal arteries and bilateral single renal arteries after catheter-based renal denervation: prospective study with 3-year follow-up. Pol Arch Intern Med 2017; 127: 423-8.
13. Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370: 1393-401.
14. Warchoł-Celińska E, Januszewicz A, Prejbisz A, et al, Renal denervation after the symplicity HTN-3 trial. Postep Kardiol Interw 2014; 10: 75-7.
15. Luscher TF, Mahfoud F. Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? Eur Heart J 2014; 35: 1706-11.
16. Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol 2012; 59: 901-9.
17. Ukena C, Mahfoud F, Spies A, et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol 2013; 167: 2846-51.
18. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension 2012; 60: 419-24.
19. Schlaich MP, Straznicky N, Grima M, et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome? J Hypertens 2011; 29: 991-6.
20. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52: 1749-57.
21. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al. Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005; 18: 805-12.
22. Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 2001; 161: 2661-7.
23. Hering D, Esler MD, Schlaich MP. Effects of renal denervation on insulin resistance. Expert Rev Cardiovasc Ther 2012; 10: 1381-6.
24. Bramlage, P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004; 17: 904-10.
25. Hall JE. The kidney, hypertension, and obesity. Hypertension 2003; 41: 625-33.
26. Schlaich MP, Hering D, Sobotka P, et al. Effects of renal denervation on sympathetic activation, blood pressure, and glucose metabolism in patients with resistant hypertension. Front Physiol 2012; 3: 10.
27. Davies JE, Manisty CH, Petraco R, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol 2013; 162: 189-92.
28. Hering D, Lambert EA, Marusic P, et al. Renal nerve ablation reduces augmentation index in patients with resistant hypertension. J Hypertens 2013; 31: 1893-900.
29. Qiu M, Yin Y, Shan Q. Renal sympathetic denervation versus antiarrhythmic drugs for drug-resistant hypertension and symptomatic atrial fibrillation (RSDforAF) trial: study protocol for a randomized controlled trial. Trials 2013; 14: 168.
30. Ukena C, Mahfoud F, Linz D, et al. Potential role of renal sympathetic denervation for the treatment of cardiac arrhythmias. EuroIntervention 2013; 9 Suppl R: R110-6.
Copyright: © 2018 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe